Citigroup
NVLN

Citigroup’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Citigroup’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,100
Closed -$3K – 7926
2018
Q3 		$3K Sell
1,100
-32,620
-97% -$115K ﹤0.01% 7584
2018
Q2 		$124K Buy
33,720
+30,549
+963% +$123K ﹤0.01% 5519
2018
Q1 		$11K Buy
3,171
+934
+42% +$3.96K ﹤0.01% 7035
2017
Q4 		$7K Buy
2,237
+2,234
+74,467% +$10.7K ﹤0.01% 7166
2017
Q3 		$0 Sell
3
-4,908
-100% -$39.3K ﹤0.01% 7570
2017
Q2 		$45K Buy
4,911
+16
+0.3% +$154 ﹤0.01% 5868
2017
Q1 		$52K Sell
4,895
-2,120
-30% -$21.7K ﹤0.01% 5675
2016
Q4 		$59K Buy
+7,015
New +$62.1K ﹤0.01% 6071

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's NVLN Position: Q4 2018 in Review

Citigroup sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 1,100 shares — an estimated $3K sold.

Citigroup first reported a position in NVLN in Q4 2016 and held it in 8 quarters. The position peaked at $124K in Q2 2018. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

  • Citigroup reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
  • Citigroup sold 1,100 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $3K.
  • Citigroup first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 8 quarters.
  • Citigroup's Novelion Therapeutics Inc. Common Shares position peaked at $124K in Q2 2018.
  • 36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Citigroup's 13F filing for Q4 2018, filed 12 Feb 2019.